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OBJECTIVES In preparation for clinical trials of basic fibroblast growth factor (bFGF) to treat ischemic
heart disease, we sought to identify a clinically feasible method of bFGF administration.
BACKGROUND Basic FGF has been shown to promote collateral development after experimentally induced
coronary occlusion; however, methods of bFGF delivery that have been shown to be effective
in previous investigations would not be practical for clinical use.
METHODS Four randomized, blinded, controlled investigations were conducted independently and
sequentially in an established canine model. For all studies, dogs underwent operative
placement of proximal left circumflex coronary artery ameroid constrictors. The four
investigational regimens included: 1) bFGF by central venous bolus injection, 1,740 mg/day
for one, two or seven days; 2) bFGF by intravenous infusion, 100 mg/kg body weight per day
for seven days; 3) bFGF by pericardial instillation, 2,000 mg/day for 7 days; and 4) bFGF by
intracoronary injection (Judkin’s technique), 100 mg/kg per day for one or two days. Each
substudy included a contemporaneous vehicle control group. Collateral perfusion (micro-
spheres) was assessed during maximal coronary vasodilation during the first month after
ameroid placement.
RESULTS Maximal collateral perfusion in dogs that received intracoronary bFGF for two days exceeded
that of concurrent control dogs by 31% (p , 0.01). Perfusion was not increased in dogs that
received single-dose intracoronary bFGF. Basic FGF administration by central venous bolus
injection, intravenous infusion and pericardial injection failed to enhance collateral perfusion.
CONCLUSIONS Administration of bFGF by the intracoronary route, an intervention that is feasible in
patients, augments collateral development in dogs. These data provide a rationale for clinical
testing of intracoronary bFGF in ischemic heart disease. (J Am Coll Cardiol 2000;35:
519–26) © 2000 by the American College of Cardiology
The facilitation of coronary collateral growth represents a
novel and potentially important therapeutic approach for
patients with ischemic heart disease. A number of angio-
genic growth factors have been evaluated experimentally as
agents to promote vascular development. Two of the most
widely studied agents, basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor, have been shown to
promote collateral development in animal models of myo-
cardial ischemia (1–5). Both agents are undergoing clinical
trials in the U.S. (6). Acidic fibroblast growth factor has
received somewhat less attention in preclinical studies, but
has been reported to increase angiographically visible col-
lateral vessels in patients undergoing surgical coronary
revascularization (7). Although there are now numerous
reports suggesting salutary biologic effects of angiogenic
growth factors in the setting of experimental myocardial
ischemia, no simple, clinically feasible method of growth
factor protein delivery has emerged as an effective means to
promote collateral development. By and large, the methods
used to administer growth factors in these studies would not
be practical in patients with ischemic heart disease. More-
over, disparities in species, experimental models, doses and
end points obfuscate meaningful comparison of the pub-
lished data. In preparation for clinical trials, we attempted to
identify an optimal method of growth factor delivery for
promotion of myocardial collateral development. We eval-
uated the biologic effects of bFGF using four clinically
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plausible routes of administration: 1) central venous bolus
injection; 2) peripheral intravenous (IV) infusion; 3) peri-
cardial instillation; and 4) intracoronary (IC) injection, the
last using standard catheter-based delivery. A secondary aim
of the study was to determine, when possible, the minimal
effective course of bFGF treatment for each delivery route.
To improve comparability across these studies, we syn-
chronized bFGF administration relative to the ischemic
stimulus and used similar bFGF doses with each route of
administration.
METHODS
Four substudies were carried out independently and sequen-
tially between November 1993 and June 1997. All proce-
dures were conducted in accordance with institutional
ethical guidelines (8). One hundred and four purpose-bred
dogs were used for the studies.
General methods. The surgical preparation of this model
has been described previously (4). Anesthesia was induced
with acepromazine, 0.2 mg/kg body weight intramuscularly
(IM), and maintained with thiopental sodium, 15 mg/kg
IV, and methoxyflurane. A thoracotomy was performed
through the left fifth intercostal space using aseptic tech-
nique. The pericardium was incised, the proximal left
circumflex coronary artery (LCx) was dissected and a 2.0- to
2.5-mm ameroid constrictor (Research Instruments Manu-
facturing, Corvallis, Oregon) was applied proximal to the
first marginal branch. A hydraulic balloon occluder was
secured around the vessel immediately distal to the ameroid.
A Silastic catheter was inserted into the left atrial (LA)
appendage. Its injection port was buried in the subcutaneous
tissue of the interscapular area, accessible for microsphere
injections. The pericardium and chest were closed, and the
animals received postoperative care with buprenorphine
analgesia as needed. Intravenous lidocaine was administered
prophylactically, and procainamide, 500 mg orally twice
daily for seven days, was administered at the discretion of
the veterinary staff. An oral broad-spectrum antibiotic was
given twice daily for seven days. Catheters were flushed with
2 to 3 ml of heparinized saline (2 U/ml) before and after test
drug administration to maintain patency.
Recombinant human bFGF was provided by Scios, Inc.
(Mountainview, California). Aliquots of bFGF and equiv-
alent volumes of saline were numerically coded and stored at
220°C until use. Aliquots were diluted with 0.5 ml of citrate
buffer immediately before administration. Weekly laboratory
studies included a complete blood count, platelet count and
levels of blood urea nitrogen, creatinine, glucose, total bilirubin,
albumin, serum glutamic-oxaloacetic transaminase, serum
glutamic-pyruvic transaminase, alkaline phosphatase, creatine
phosphokinase, calcium and phosphate.
Central venous substudy. Thirty-two dogs were used for
this study. Catheters were implanted in the right atrial (RA)
appendage; infusion ports were secured subcutaneously for
test agent administration. All dogs received seven daily
doses of the appropriate test agent (bFGF or vehicle) 10 to
16 days after ameroid placement. The dogs were random-
ized to four treatment groups (Fig. 1): group 0 served as the
control group (vehicle days 10 to 16); group 1 received
bFGF on day 16 (vehicle days 10 to 15); group 2 received
bFGF on days 14 and 16 (vehicle on alternate days); group
7 received bFGF on all 7 days. The daily bFGF dose was
1,740 mg/day (or 60 to 100 mg/kg per day on a per mass basis),
as used in our previous systemic arterial studies (4,5,9).
Peripheral IV substudy. The peripheral IV study included
25 dogs. Dogs assigned to bFGF treatment received daily
infusion of 100 mg/kg of bFGF for 7 days, 10 to 16 days
after ameroid placement (Fig. 1). The control group served
Abbreviations and Acronyms
bFGF 5 basic fibroblast growth factor
CI 5 confidence interval
IC 5 intracoronary
IM 5 intramuscular
IV 5 intravenous
IZ 5 ischemic zone
LA 5 left atrial
LCx 5 left circumflex coronary artery
NZ 5 normal zone
RA 5 right atrial
Figure 1. Summary of experimental designs and schedules for
perfusion measurements. Solid squares indicate bFGF doses
administered; open squares indicate injection of vehicle. Daily
bFGF doses by substudy: central venous: 1,740 mg/day; peripheral
IV: 100 mg/kg per day; pericardial: 2,000 mg/day; IC: 100 mg/kg
per day. Timing of perfusion measurements denoted by X. N
represents number of animals with evaluable data in each cohort.
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also as a control group for a concurrent investigation
(unpublished data) in which an alternate active drug was
administered orally. Approximately half of the control dogs
received the vehicle as a daily infusion; half received no
treatment. Appropriate volumes of coded test drugs were
added to 500 ml of 0.9% saline and infused intravenously
over 3 to 4 h through the external jugular or cephalic vein.
Pericardial substudy. Fifteen dogs were used for this
substudy. During surgical ameroid placement, the pericar-
diotomy incision was limited to ;2 cm in length. Numerous
side holes were placed in the terminal 2 cm of a 6.6F Silastic
end hole catheter (Bard Access Systems, Salt Lake City,
Utah), and the distal catheter was secured in the pericar-
dium with a pursestring suture. The pericardium was
carefully sealed to prevent leakage, and the catheter infusion
port was secured subcutaneously. In a pilot dog, not in-
cluded in the final analyses, the integrity of the pericardial
sac was evaluated 10 days after the operation by injecting a
contrast agent into the pericardial catheter under fluoro-
scopic guidance. This demonstrated free flow of contrast
agent within the pericardium without leakage. Dogs were
randomized to receive bFGF, 2,000 mg/day for seven days,
or vehicle during the period 10 to 16 days after ameroid
placement (Fig. 1).
Intracoronary substudy. Thirty-two dogs were used for
the IC substudy. Appropriate volumes of test drugs were
administered into the left main coronary artery during
cardiac catheterization using standard the Judkin’s tech-
nique. The dogs were randomized to three cohorts: bFGF
100 mg/kg 3 1 (day 16); bFGF 100 mg/kg 3 2 (days 14 and
16); or vehicle on one of these two schedules (Fig. 1). Before
catheterization, the dogs were briefly anesthetized with a
short-acting barbiturate, intubated and mechanically venti-
lated. Anesthesia was maintained with isoflurane. Blood
pressure and an electrocardiogram (ECG) were monitored
throughout the procedure. The groin was shaved and
prepped, and a 5F Cordis introducer catheter was inserted
percutaneously in the femoral artery. Cardiac catheteriza-
tion was performed in standard fashion. Contrast material
(hexabrix, 3 to 5 ml, diluted 1:1) was injected to ensure
engagement of the left main coronary artery. Occlusion of
the LCx was confirmed by a lack of anterograde flow
beyond the ameroid constrictor. Test drugs were injected
over 2 min. The catheter was flushed with saline before and
after test drug injection, and an additional contrast injection
was performed after test drug injection to document main-
tenance of the catheter’s position. Heparin was not used
during catheterization.
Randomization, blinding and end points. Blocked ran-
domization was used in all studies. Investigators responsible
for surgical instrumentation, animal care, test agent and
microsphere injections, data analysis and interpretation had
no knowledge of treatment group. Technical problems
precluded data interpretation in some animals; decisions to
exclude nonevaluable data were made without knowledge of
treatment assignment. For all studies, the primary prospec-
tively defined end points were maximal coronary conduc-
tance in the collateral-dependent zone (the quotient of
perfusion and arterial pressure) and the ischemic zone/
normal zone (IZ/NZ) perfusion ratio. Regional myocardial
perfusion was quantified during pharmacologically induced
maximal coronary vasodilation. Maximal vascular conduc-
tance (perfusion divided by mean arterial pressure) was
selected as the primary surrogate of collateral development
because it could be assessed: 1) in the conscious state, in the
absence of confounding influences of anesthesia or surgery,
or both; 2) on a serial basis; and 3) during reproducible
vasodilatory stress.
Study procedures. The dogs were sedated with aceproma-
zine, 0.1 to 0.25 mg/kg IM, or diazepam, 1 to 2 mg/kg IV,
or both. Using local lidocaine anesthesia, a 5F Cordis
introducer catheter was inserted into the left or right
femoral artery for reference blood sample withdrawal. Ar-
terial blood pressure was measured through the catheter side
port, and the ECG was continuously recorded. Maximal
coronary vasodilation was induced with chromonar hydro-
chloride, 8 mg/kg, infused through the LA catheter over 20
to 30 min. Regional perfusion was assessed using the
reference sample technique, as we have done previously
(1,2,4,5). Microspheres were randomly selected from four
isotopes (New England Nuclear, Boston, Massachusetts;
central venous and IC studies) or eight dual-fluorescent
labels (Triton Technology, San Diego, California; periph-
eral IV and pericardial studies). Approximately 3 to 4 3 106
microspheres, 15 mm in diameter, were injected into the LA
catheter with simultaneous withdrawal of a femoral artery
reference sample at 7.75 ml/min. Complete LCx occlusion
requires ;10 to 20 days after ameroid placement. There-
fore, during assessment of collateral perfusion on days 10
and 17, the hydraulic balloon occluder was temporarily
inflated 15 s before the injection of microspheres to arrest
residual anterograde LCx flow. The occluder was perma-
nently inflated on day 24 to ensure timely and complete
LCx occlusion. The schedule for determination of regional
myocardial perfusion for all studies is summarized in Figure
1. The final myocardial perfusion assessments in the periph-
eral IV, pericardial and IC studies were determined in
duplicate using a second labeled microsphere, generally
injected within 5 min of the first microsphere injection. On
completion of the final microsphere injections, the dogs
were anesthetized with sodium pentobarbital. Heparin
(5,000 IU) and adenosine (250 mg) were administered
intravenously, followed by 40 mEq of potassium chloride to
arrest the hearts. The hearts were removed and perfusion-
fixed at 100 mm Hg with 10% buffered formaldehyde.
Calculation of myocardial perfusion. For studies using
radiolabeled microspheres, the hearts were analyzed as
previously described (1,2). For experiments in which fluo-
rescent microspheres were used, a single 7-mm left ventric-
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ular slice was divided into 16 samples, which were digested
and analyzed by Interactive Medical Technologies (La Jolla,
California).
Infarct size. Infarct size was formally quantified in the
central venous substudy. The short-axis slice basal to the
two central slices was analyzed. Radial wedges were
paraffin-embedded and stained using Masson’s trichrome
method to differentially stain viable myocardium (red)
versus scar (blue). The sections were examined in their
entirety using a microscope fitted with a 13 objective lens.
Rectangular fields were digitized in true color, and areas of
scarred myocardium were quantified using computer-based
image analysis. Total tissue area was determined using a
macro lens, and infarct area was computed as the quotient of
scarred area/total tissue area 3100%. For other substudies,
infarct size was estimated by inspection of the fixed slices to
identify dogs with extensive infarcts.
Statistical methods. Continuous data are summarized as
the mean value 6SE. Differences between the mean values
of two groups were analyzed using the Student t test for
unpaired data (two-tailed). For the IC substudy, there were
two active treatment groups and one control group. Differ-
ences between the mean values of three groups were assessed
using single-factor analysis of variance followed by individ-
ual t tests and the Bonferroni correction. Thus, there were
three salient comparisons (bFGF 31 vs. control; bFGF 32
vs. control; bFGF 32 vs. bFGF 31), and p values were
multiplied by a factor of 3, with alpha set at 0.05. Relative
differences between two groups are expressed as mean
percent differences 695% confidence interval (CI).
RESULTS
Evaluable perfusion data were obtained from 93 (89%) of
104 dogs. Seven deaths occurred before treatment assign-
ment: three deaths were within the first two weeks after the
operation, presumed secondary to abrupt or premature
ameroid-induced LCx occlusion; two deaths were attributed
to anesthesia after cardiac catheterization in the IC study;
and two deaths were related to inadvertent lidocaine over-
dose in the IV study. Four dogs were excluded after
perfusion data were obtained—two because of technical
problems and two because of unusually extensive infarcts.
Generally, bFGF was well tolerated by dogs that received
only one or two doses of the peptide by any route; however,
anorexia, vomiting and excessive thirst were observed by the
veterinary staff in the majority of dogs after repeated
administration of the 100 mg/kg dose of bFGF.
Hemodynamic data. Systemic hemodynamic data were
obtained 10, 17, 24 and 38 days after ameroid placement in
the central venous study. There were no significant changes
in mean arterial pressure or heart rate with respect to time
and no significant intergroup differences (data not shown).
In the peripheral IV study, heart rate and mean arterial
pressure were similar in the two groups before treatment
(day 10). At end-treatment (day 17), there was a significant
reduction in systolic blood pressure in bFGF-treated dogs
(212%; 95% CI 23% to 222%), associated with an
increase in heart rate (32%; 95% CI 10% to 54%). Interest-
ingly, bFGF-treated dogs exhibited sustained reductions in
mean arterial pressure up to three weeks after the conclusion
of bFGF treatment. Reductions of 17 6 11%, 20 6 12%
and 13 6 10% were observed on days 24, 31 and 38,
respectively (mean percent decrease 695% CI). Systolic and
diastolic blood pressures were proportionately decreased.
Hemodynamic measurements were obtained only at the end
of the pericardial and IC studies, and there were no
significant differences between groups (data not shown).
The early hemodynamic response to bFGF administration
was not assessed.
Infarct size. Three dogs in the central venous substudy had
significant infarcts, ;18%, 15% and 6% in area, whereas the
remainder of the dogs had insignificant scarring, ,2% of
the left ventricle, and generally ,1%. There was no relation
between treatment group and infarct size. One dog in each
of the peripheral IV and IC substudies had notable infarcts.
Both animals were excluded from further analyses.
Collateral perfusion. The IZ and NZ conductances for
the central venous and peripheral IV substudies are sum-
marized in Tables 1 and 2, respectively. In both substudies,
maximal NZ conductance was similar in all groups and did
not change significantly over time. Maximal IZ conductance
and IZ/NZ perfusion ratios increased in all groups with
respect to time; however, there were no significant inter-
group differences. In the pericardial substudy, there were no
differences between bFGF- and saline-treated dogs with
respect to maximal IZ conductance or IZ/NZ ratios (Table
3). For the IC substudy (Table 4), maximal NZ conduc-
tance was similar in all groups. Mean IZ/NZ perfusion
ratios were 0.45 6 0.02, 0.36 6 0.03 and 0.34 6 0.02 in the
bFGF 32, bFGF 31 and vehicle cohorts, respectively.
Analysis of variance was significant at p 5 0.0084, with
significant differences between the bFGF 32 and control
groups (p 5 0.0024) and the bFGF 32 and bFGF 31
groups (p 5 0.017). After application of the Bonferroni
correction, the difference between the bFGF 32 and
control groups remained highly statistically significant (p 5
0.0072), whereas the difference between the bFGF 32 and
bFGF 31 groups did not (p 5 0.051). For comparison
between the bFGF 32 and control groups, the relative
percent difference in perfusion ratios was 31% (95% CI 12%
to 49%).
Laboratory data. Administration of one or two bFGF
doses by IC or central venous routes was not associated with
significant hematologic or biochemical abnormalities. Sig-
nificant toxicity was limited to cohorts that received seven-
dose bFGF regimens by the central venous, IV or pericardial
routes. As in previous studies (4,5), the most pronounced
effects were hematologic. Transient thrombocytopenia and
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anemia were observed after bFGF 37 doses by both the
central venous and peripheral IV routes, although they were
not observed with the pericardial route. For dogs that
received central venous bFGF 37 doses, the platelet count
decreased from 240 6 17 3 103/ml before treatment to
150 6 24 3 103/ml during the week of treatment, normal-
izing one week later. Thrombocytopenia was quantitatively
similar with peripheral IV bFGF. A decrease in hemoglobin
was observed one week after cessation of treatment in dogs
that received central venous bFGF 37 doses (mean decrease
’2.8 g/dl to a nadir of 11.8 6 0.4 g/dl), with partial
recovery during the next two weeks. Anemia was also
associated with the seven-dose peripheral IV bFGF regi-
men, although the nadir in hemoglobin was less pronounced
(13.7 6 0.4 g/dl vs. 15.5 6 0.4 bFGF vs. control, p , 0.02)
and delayed until the final week of the study. Moderate
leukocytosis was observed in dogs that received peripheral
IV and pericardial bFGF, although the changes reached
statistical significance only in the pericardial substudy. In
the peripheral IV substudy, leukocytosis peaked the week
after IV bFGF administration and was largely due to
granulocytosis and monocytosis (peak white blood cell count
17.3 6 2.3 vs. 12.2 6 1.2 3 103/ml, bFGF vs. control
group, p 5 0.053). Similar changes in leukocyte count were
observed in the dogs that received pericardial bFGF (peak
white blood cell count during treatment 17.0 6 1.7 vs.
12.3 6 0.5 3 103/ml, bFGF vs. control group, p , 0.05),
with no apparent difference thereafter. Pericardial bFGF
administration was associated with transient hypoalbumin-
emia and elevated serum glutamic-pyruvic transaminase
during the week after treatment. The nadir in serum
albumin was 2.5 6 0.1 g/dl (vs. 3.0 6 0.1 g/dl in control
group, p , 0.005), with a peak serum glutamic-pyruvic
transaminase level of 103 6 16 (vs. 39 6 16 IU/liter in
control group, p , 0.02).
DISCUSSION
A number of investigations have suggested that angiogenic
growth factors can enhance collateral function in the setting
of experimental coronary artery occlusion; however, the
methods of growth factor protein administration used to
date are not well suited for routine clinical use. This
investigation provides the first evidence, to our knowledge,
that recombinant growth factor protein, administered
through a clinically practical route, can enhance myocardial
collateral development in vivo. Although bFGF by the IC
route improved collateral perfusion, it was ineffective when
administered by the peripheral or central venous routes or
when administered by the intrapericardial route.
We previously demonstrated that IC bFGF (1) and
vascular endothelial growth factor (2) promote coronary
collateral development in a similar model; however, multiple
doses of the growth factors were instilled directly into the
collateral-dependent area, distal to the point of coronary
occlusion, a near impossibility in patients with coronary
disease. More recently, we found that bFGF improved
collateral perfusion when administered repeatedly by a
systemic arterial route (LA injection) (4,5), but repeated LA
access represents a major, practical obstacle. Other investi-
gators have studied sustained-release polymers for local
growth factor delivery (3). These polymers have potential
for adjunctive use during the course of surgical coronary
revascularization, but presently require invasive techniques
for deployment.
Intravenous bFGF. Basic FGF is a heparin-binding
growth factor that binds avidly to glycosaminoglycans in
vascular subendothelial matrix (10). Given the vast cross-
sectional area of the pulmonary circulation, there exists the
potential for substantial first-pass lung uptake of intrave-
nously administered bFGF. When we recapitulated our
previous systemic arterial study (5), shifting only the site of
bFGF administration from the LA to the RA, there was no
measurable effect on collateral function. Given the impor-
tant clinical ramifications of these findings, and in recogni-
tion of the limited statistical power of the central venous
substudy, the peripheral IV substudy was performed as a
confirmatory investigation. Again, there was no evidence of
a salutary effect. Our ability to replicate these findings in
independent but related studies suggests that it is unlikely
that a biologically meaningful effect was missed by chance.
Anemia and thrombocytopenia were observed in bFGF-
treated cohorts in both of these substudies, quantitatively
similar to those incidences observed in the previous systemic
arterial investigation (5). Thus, for intravenous bFGF, there
was no evidence of a beneficial effect, even at doses associ-
ated with hematologic toxicity.
Previously, we observed both short- and long-term blood
pressure–lowering effects of bFGF (4). Only long-term
Table 3. Final Coronary Collateral Conductance and the IZ/NZ Perfusion Ratio (Pericardial
Study)
bFGF (n 5 8) Saline (n 5 7)
Conductance*
IZ/NZ
Conductance
IZ/NZIZ NZ IZ NZ
2.07 6 0.28 5.44 6 0.75 0.39 6 0.03 1.84 6 0.13 5.13 6 0.44 0.37 6 0.03
*Conductance is expressed as ml/min per 100 g per mm Hg. Ischemic zone (IZ) and normal zone (NZ) myocardial conductance
and the IZ/NZ ratio at day 38 in basic fibroblast growth factor (bFGF)- and saline-treated dogs. Data are presented as the mean
value 6 SEM.
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changes were assessed in the present investigation. Although a
prolonged decrease in blood pressure was observed in bFGF-
treated dogs in the peripheral IV substudy, a long-term
hemodynamic effect was not detected in the central venous
substudy. The explanation for this disparity is unknown.
Pericardial bFGF. The pericardial space has been consid-
ered as a target for gene transfer of angiogenic growth
factors (11,12). Intrapericardial bFGF has been reported to
induce localized increases in myocardial vascularity in rab-
bits (13) and to reduce infarct size in a canine model (14).
Conceptually, the pericardium could function as a paracrine
organ, storing and releasing bFGF to the developing col-
lateral circulation. Recently, we calculated that 19% of a
pericardial dose of radiolabeled bFGF could be recovered
from the myocardium after 150 min (15), suggesting that
this route would be effective. Our findings, however, are
counter to this prediction. This may relate to the manner of
bFGF presentation to vascular cells or the potential for
pericardial inflammatory mediators to cause peptide degra-
dation, or both. Consistent with the latter hypothesis,
elevated peripheral polymorphonuclear leukocyte counts
were observed in bFGF-treated dogs in the pericardial
substudy, suggesting a proinflammatory state. Moreover,
this premise is supported by the fact that intrapericardial
bFGF did not induce blood pressure lowering, anemia or
thrombocytopenia characteristic of systemic arterial and
intravenous bFGF administration.
Ostensibly, our findings appear inconsistent with those of
Landau et al. (13) and Uchida et al. (14). The former study
assessed the effect of pericardial bFGF infusion during and
after IV angiotensin II treatment (13). Angiotensin II was
administered to induce left ventricular hypertrophy, thereby
decreasing capillary density and inducing ischemia. Localized
increases in epicardial vascularity were observed with bFGF
administration. Uchida et al. reported a decreased infarct size
associated with intrapericardial administration of bFGF in a
canine model of inorganic mercury left anterior descending
coronary artery embolization (14). Neither of these studies
were designed to evaluate collateral development or collateral
perfusion, however, and it would be an overstatement to
conclude that our results are discordant with either.
Intracoronary bFGF. The bFGF dose was normalized to
body mass (100 mg/kg) for the IC substudy, approximating
the doses given in previous investigations (4,5). Adminis-
tration of two but not one 100 mg/kg bFGF dose was
associated with significant enhancement of collateral perfu-
sion. Parenthetically, it should be noted that the IZ/NZ
ratio for the IC substudy control group is somewhat lower
than that of the control groups in the other substudies, likely
because the final perfusion assessment was made on day 33
in the IC substudy, whereas it was made later (on day 38) in
the other substudies. The mean day 33 IZ/NZ ratio
observed in IC substudy control animals is virtually identical
to that found in control animals at a similar time point (day
31) in previous studies (4).Ta
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Route of administration is an important determinant of
response. These investigations provide evidence that the
location of bFGF administration is a critical determinant of
bFGF’s biologic activity, consistent with our previous ob-
servation that myocardial bFGF levels are determined prin-
cipally by the proximity of injection (15). When iodine-
125–labeled bFGF was injected into the left anterior
descending coronary artery of dogs, bFGF activity in the
territory of the injected artery was approximately sevenfold
higher than that of the myocardium of the uninjected,
control area (15). This concept is consistent with our
observations across numerous investigations: bFGF has
promoted collateral development when administered by the
IC route (in the present IC substudy, as well as in a previous
study [1]) and by the systemic arterial (LA) route (4,5);
however, no effect was observed using the peripheral or
central venous routes. The pericardial substudy represents
the single exception to this principle, for the possible
reasons discussed earlier. In contrast, bFGF toxicity appears
to be largely route-independent, related to cumulative dose
and/or duration of exposure, although the pericardial route
is again an exception.
Study limitations and implications for clinical trials.
Previously, we demonstrated the importance of ischemia or
a transcollateral pressure gradient, or both, as primers for
bFGF-induced collateral expansion (9). Basic FGF admin-
istration enhanced collateral perfusion when synchronized
with the period of progressive coronary occlusion, but not
when administered six months later. The present set of
investigations provides evidence that proximity of injection
is likewise a critical determinant of bFGF’s biologic activity.
Thus, taken together, these studies suggest that optimal
treatment would involve IC bFGF delivery during periods
of myocardial ischemia, a matter of considerable practical
importance for the design of clinical trials.
We have confirmed the ability of bFGF to promote
collateral development when administered to healthy dogs
subjected to progressive, single coronary artery occlusion
whose coronary arteries are otherwise normal. These ani-
mals undergo a natural program of collateral development
and appear to be responsive to the effects of IC bFGF. At
the other end of the spectrum are dogs with mature
collateral vessels—these animals are unresponsive to bFGF
administration (9). It is possible that patients with chronic
stable angina lie somewhere between these extremes, man-
ifesting intermittent ischemia that could provide opportu-
nities for bFGF responsiveness.
Conclusions. We have established proof of concept of
bFGF-induced myocardial coronary collateral expansion
using a clinically feasible IC route of bFGF administration;
however, it is not known to what extent the results of these
experiments can be extrapolated to the complex milieu of
human ischemic heart disease. This is a question that can
only be addressed through clinical trials.
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